WO2014138426A3 - Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes - Google Patents

Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes Download PDF

Info

Publication number
WO2014138426A3
WO2014138426A3 PCT/US2014/021288 US2014021288W WO2014138426A3 WO 2014138426 A3 WO2014138426 A3 WO 2014138426A3 US 2014021288 W US2014021288 W US 2014021288W WO 2014138426 A3 WO2014138426 A3 WO 2014138426A3
Authority
WO
WIPO (PCT)
Prior art keywords
adipocytes
compositions
methods
body fat
reducing body
Prior art date
Application number
PCT/US2014/021288
Other languages
English (en)
Other versions
WO2014138426A2 (fr
Inventor
Murat V. Kalayoglu
Michael S. Singer
Original Assignee
Topokine Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topokine Therapeutics, Inc. filed Critical Topokine Therapeutics, Inc.
Publication of WO2014138426A2 publication Critical patent/WO2014138426A2/fr
Publication of WO2014138426A3 publication Critical patent/WO2014138426A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des procédés et des compositions pour la réduction de la graisse corporelle et/ou des adipocytes chez un sujet, comprenant l'administration d'un composé et/ou d'un extrait de produit naturel qui est un activateur de la kinase activée par l'adénosine monophosphate (AMPK).
PCT/US2014/021288 2013-03-07 2014-03-06 Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes WO2014138426A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773942P 2013-03-07 2013-03-07
US61/773,942 2013-03-07

Publications (2)

Publication Number Publication Date
WO2014138426A2 WO2014138426A2 (fr) 2014-09-12
WO2014138426A3 true WO2014138426A3 (fr) 2014-10-30

Family

ID=51492097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/021288 WO2014138426A2 (fr) 2013-03-07 2014-03-06 Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes

Country Status (1)

Country Link
WO (1) WO2014138426A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738729T3 (es) * 2014-09-01 2020-01-24 Vidya Herbs Pvt Ltd Extracto de Mangifera para la gestión de la obesidad y/o el peso
EP3124047A1 (fr) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Triterpénoïdes pentacycliques pour lipolyse par injection
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
IL257784B2 (en) * 2015-08-28 2023-11-01 Caliway Biopharmaceuticals Co Ltd Methods and compositions for reducing fat
US10369179B2 (en) 2015-09-13 2019-08-06 Vidya Herbs, Inc. Composition of Mangifera indica
FR3042411B1 (fr) * 2015-10-20 2019-07-12 Valbiotis Composition comprenant un melange de molecules particulieres et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
WO2018037384A1 (fr) * 2016-08-26 2018-03-01 康霈生技股份有限公司 Injection sous-cutanée pour réduire le poids corporel et application associée
US11896600B2 (en) 2019-09-21 2024-02-13 Vidya Herbs, Inc. Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136785A1 (en) * 2000-11-07 2002-09-26 Chun-Su Yuan Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity
WO2003011267A1 (fr) * 2001-07-31 2003-02-13 The Nisshin Oillio, Ltd. Medicaments anti-obesite et ses substances
US20030212014A1 (en) * 2000-08-09 2003-11-13 Neil Ruderman Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
WO2007081808A2 (fr) * 2006-01-05 2007-07-19 Deviris Inc. Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
US20080004217A1 (en) * 1998-12-30 2008-01-03 Applied Research Systems Ars Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy
US20100152275A1 (en) * 2008-12-11 2010-06-17 Kaloness, Inc. Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals
WO2011152692A2 (fr) * 2010-06-03 2011-12-08 주식회사 리스토어랩스 Composition de crème anti-obésité contenant de la fucoxanthine
TW201231046A (en) * 2011-01-25 2012-08-01 Univ Nat Cheng Kung Pharmaceutical composition or Toona sinensis extract for decreasing weight or body fat

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004217A1 (en) * 1998-12-30 2008-01-03 Applied Research Systems Ars Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy
US20030212014A1 (en) * 2000-08-09 2003-11-13 Neil Ruderman Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
US20020136785A1 (en) * 2000-11-07 2002-09-26 Chun-Su Yuan Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity
WO2003011267A1 (fr) * 2001-07-31 2003-02-13 The Nisshin Oillio, Ltd. Medicaments anti-obesite et ses substances
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
WO2007081808A2 (fr) * 2006-01-05 2007-07-19 Deviris Inc. Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
US20100152275A1 (en) * 2008-12-11 2010-06-17 Kaloness, Inc. Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals
WO2011152692A2 (fr) * 2010-06-03 2011-12-08 주식회사 리스토어랩스 Composition de crème anti-obésité contenant de la fucoxanthine
TW201231046A (en) * 2011-01-25 2012-08-01 Univ Nat Cheng Kung Pharmaceutical composition or Toona sinensis extract for decreasing weight or body fat

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
CARLOS ROBERTO PORTO DECHANDT ET AL.: "Combretum lanceolatum flowers extract shows antidiabetic activity through activation of AMPK by quercetin.", BRAZILIAN JOURNAL OF PHARMACOGNOSY., vol. 23, no. 2, 2013, pages 291 - 300, XP018506527 *
CHEN YY. ET AL.: "Methyl cinnamate inhibits adipocyte differentiation via activation of the CaMKK2-AMPK pathway in 3T3-Ll preadipocytes", J AGRIC CHEM, vol. 60, no. 4, 2012, pages 955 - 963 *
CHI Y ET AL.: "Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase''.", J PHARMACOL EXP THER., vol. 339, no. 1, October 2011 (2011-10-01), pages 257 - 266 *
HA DO T ET AL.: "Adlay seed extract (Coix lachryma-jobi L.) decreased adipocyte differentiation and increased glucose uptake in 3T3-L1 cells''.", J MED FOOD., vol. 13, no. 6, December 2010 (2010-12-01), pages 1331 - 1339 *
HA DO T ET AL.: "The selected flavonol glycoside derived from Sophorae Flos improves glucose uptake and inhibits adipocyte differentiation via activation AMPK in 3T3-L1 cells''.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 20, 2010, pages 6076 - 6081, XP027291116 *
HUANG B. ET AL.: "Cinnamaldehyde prevents adipocyte differentiation and adipogenesis via regulation of peroxisome proliferator-activated receptor-y (PPARy) and AMP - activated protein kinase (AMPK) pathways''.", J AGRIC FOOD CHEM, vol. 59, no. 8, 2011, pages 3666 - 3673 *
JUNG KH ET AL.: "Ganoderma lucidum extract stimulates glucose uptake in L6 rat skeletal muscle cells''.", ACTA BIOCHIM POL., vol. 53, no. 3, 2006, pages 597 - 601 *
KIM DY ET AL.: "Boesenbergia pandurata attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism''.", INT J MOL SCI., vol. 13, no. 1, 2012, pages 994 - 1005 *
LEE NY ET AL.: "Inhibitory Effect of Vitamin U (S-Methylmethionine Sulfonium Chloride) on Differentiation in 3T3-L1 Pre-adipocyte Cell Lines", ANN DERMATOL., vol. 24, no. 1, 2012, pages 39 - 44 *
MCCARTY MF.: "Hepatothermic therapy of obesity: rationale and an inventory of resources''.", MED HYPOTHESES., vol. 57, no. 3, 2001, pages 324 - 336, XP009030758, DOI: doi:10.1054/mehy.2000.1322 *
NINOMIYA K ET AL.: "Potent anti-obese principle from Rosa canina: structural requirements and mode of action of trans-tiliroside''.", BIOORG MED CHEM LETT., vol. 17, no. 11, 2007, pages 3059 - 3064, XP022068393, DOI: doi:10.1016/j.bmcl.2007.03.051 *
ONG KW ET AL.: "Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes. art e32718", PLOS ONE., vol. 7, no. 3, 2012, pages 1 - 11 *
ONO M ET AL.: "Antiadipogenic effect of dietary apigenin through activation of AMPK in 3T3-L1 cells''.", J AGRIC FOOD CHEM., vol. 59, no. 24, 28 December 2011 (2011-12-28), pages 13346 - 13352 *
PU P ET AL.: "Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet''.", ARCH BIOCHEM BIOPHYS., vol. 518, no. 1, 1 February 2012 (2012-02-01), pages 61 - 70 *
SEO JB ET AL.: "Foenumoside B from Lysimachia foenum-graecum inhibits adipocyte differentiation and obesity induced by high-fat diet", BIOCHEM BIOPHYS RES COMMUN., vol. 417, no. 2, 13 January 2012 (2012-01-13), pages 800 - 806 *
SHAH SS ET AL.: "Effect of piperine in the regulation of obesity-induced dyslipidemia in high-fat diet rats''.", INDIAN J PHARMACOL., vol. 43, no. 3, 2011, pages 296 - 299, XP009180479, DOI: doi:10.4103/0253-7613.81516 *
TAESUN PARK ET AL.: "Phytochemicals as Potential Agents for Prevention and Treatment of Obesity and Metabolic Diseases.", ANTI-OBESITY DRUG DISCOVERY AND DEVELOPMENT, vol. 1, 2011, pages 1 - 48 *
YU LI ET AL.: "AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-induced Insulin Resistant Mice.", CELL METAB., vol. 13, no. 4, 6 April 2011 (2011-04-06), pages 376 - 388, XP028208831, DOI: doi:10.1016/j.cmet.2011.03.009 *
ZHANG F ET AL.: "Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice''.", PHARMACOL RES., vol. 57, no. 4, April 2008 (2008-04-01), pages 318 - 323, XP022637167, DOI: doi:10.1016/j.phrs.2008.03.002 *
ZHANG Y ET AL.: "Identification of benzophenone C-glucosides from mango tree leaves and their inhibitory effect on triglyceride accumulation in 3T3-L1 adipocytes''.", J AGRIC FOOD CHEM., vol. 59, no. 21, 9 November 2011 (2011-11-09), pages 11526 - 11533 *

Also Published As

Publication number Publication date
WO2014138426A2 (fr) 2014-09-12

Similar Documents

Publication Publication Date Title
WO2014138426A3 (fr) Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes
HK1246800A1 (zh) 用於營養組合物的寡糖組合物和其製造方法
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
IL242934B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EP2964230A4 (fr) Inhibiteurs de kinases de lignée mixte et procédés thérapeutiques
EP3013348A4 (fr) Composition médicamenteuse constituée d'un extrait d'amarante à teneur enrichie en nitrate et son procédé de préparation
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
HK1216866A1 (zh) 含有富含類胡蘿蔔素的運動節桿菌提取物的化妝品、藥物或食品組合物
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
AU2018201444B2 (en) High fat human milk products
SG11201509738RA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
PH12015502242A1 (en) Lutein composition suitable for infant food formulations
MX369122B (es) Suplementos herbales y métodos para utilizar los mismos.
IN2014DE02625A (fr)
MY181719A (en) Fragrance and flavor compositions comprising neopentyl glycol diacetate
CA3056612A1 (fr) Analogues de deutetrabenazine, leur preparation et leur utilisation
MX2015016603A (es) Composiciones de corticosteroides.
EP3027070A4 (fr) Compositions et leur utilisation pour le sevrage tabagique et autres traitements
EP3528892A4 (fr) Composition multivitaminique enrichie en antioxydants, et méthodes d'utilisation
PH12017501979A1 (en) Pharmaceutical compound
MY193591A (en) Standardised extract of labisia pumila for weight reduction and nano-formulation thereof
MA40369A (fr) Applications de l'extrait de cistanche tubulosa dans la préparation d'un médicament ou produit de protection les cellules de l'œil
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14759616

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14759616

Country of ref document: EP

Kind code of ref document: A2